Genenta Science S.p.A.

NASDAQ: GNTA · Real-Time Price · USD
4.25
0.08 (1.85%)
At close: May 06, 2025, 3:57 PM
4.25
0.00%
After-hours: May 06, 2025, 04:00 PM EDT
1.85%
Bid 3.97
Market Cap 77.73M
Revenue (ttm) n/a
Net Income (ttm) -8.92M
EPS (ttm) -0.55
PE Ratio (ttm) -7.73
Forward PE -5.42
Analyst Buy
Ask 4.29
Volume 2,935
Avg. Volume (20D) 20,458
Open 4.17
Previous Close 4.17
Day's Range 4.17 - 4.25
52-Week Range 2.79 - 7.28
Beta 0.65

About GNTA

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indic...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 15, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol GNTA
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for GNTA stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 488.24% from the latest price.

Stock Forecasts
7 months ago
+9.56%
Genenta Science shares are trading higher after th... Unlock content with Pro Subscription